S&P 500   3,393.64 (-0.22%)
DOW   27,506.66 (-0.65%)
QQQ   282.30 (+0.65%)
AAPL   116.28 (+1.07%)
MSFT   213.74 (+1.74%)
FB   283.00 (+2.13%)
GOOGL   1,592.29 (+0.50%)
AMZN   3,273.50 (+2.07%)
TSLA   422.36 (+0.49%)
NVDA   532.80 (+1.36%)
BABA   317.72 (+3.54%)
CGC   18.74 (+1.13%)
GE   7.18 (-2.71%)
MU   52.06 (-0.15%)
AMD   78.17 (-4.94%)
T   27.06 (-1.17%)
F   7.96 (-0.87%)
ACB   4.07 (-7.50%)
GILD   59.90 (-0.10%)
NFLX   487.17 (-0.22%)
NIO   27.86 (+7.11%)
BA   156.44 (-2.73%)
DIS   123.59 (-0.38%)
S&P 500   3,393.64 (-0.22%)
DOW   27,506.66 (-0.65%)
QQQ   282.30 (+0.65%)
AAPL   116.28 (+1.07%)
MSFT   213.74 (+1.74%)
FB   283.00 (+2.13%)
GOOGL   1,592.29 (+0.50%)
AMZN   3,273.50 (+2.07%)
TSLA   422.36 (+0.49%)
NVDA   532.80 (+1.36%)
BABA   317.72 (+3.54%)
CGC   18.74 (+1.13%)
GE   7.18 (-2.71%)
MU   52.06 (-0.15%)
AMD   78.17 (-4.94%)
T   27.06 (-1.17%)
F   7.96 (-0.87%)
ACB   4.07 (-7.50%)
GILD   59.90 (-0.10%)
NFLX   487.17 (-0.22%)
NIO   27.86 (+7.11%)
BA   156.44 (-2.73%)
DIS   123.59 (-0.38%)
S&P 500   3,393.64 (-0.22%)
DOW   27,506.66 (-0.65%)
QQQ   282.30 (+0.65%)
AAPL   116.28 (+1.07%)
MSFT   213.74 (+1.74%)
FB   283.00 (+2.13%)
GOOGL   1,592.29 (+0.50%)
AMZN   3,273.50 (+2.07%)
TSLA   422.36 (+0.49%)
NVDA   532.80 (+1.36%)
BABA   317.72 (+3.54%)
CGC   18.74 (+1.13%)
GE   7.18 (-2.71%)
MU   52.06 (-0.15%)
AMD   78.17 (-4.94%)
T   27.06 (-1.17%)
F   7.96 (-0.87%)
ACB   4.07 (-7.50%)
GILD   59.90 (-0.10%)
NFLX   487.17 (-0.22%)
NIO   27.86 (+7.11%)
BA   156.44 (-2.73%)
DIS   123.59 (-0.38%)
S&P 500   3,393.64 (-0.22%)
DOW   27,506.66 (-0.65%)
QQQ   282.30 (+0.65%)
AAPL   116.28 (+1.07%)
MSFT   213.74 (+1.74%)
FB   283.00 (+2.13%)
GOOGL   1,592.29 (+0.50%)
AMZN   3,273.50 (+2.07%)
TSLA   422.36 (+0.49%)
NVDA   532.80 (+1.36%)
BABA   317.72 (+3.54%)
CGC   18.74 (+1.13%)
GE   7.18 (-2.71%)
MU   52.06 (-0.15%)
AMD   78.17 (-4.94%)
T   27.06 (-1.17%)
F   7.96 (-0.87%)
ACB   4.07 (-7.50%)
GILD   59.90 (-0.10%)
NFLX   487.17 (-0.22%)
NIO   27.86 (+7.11%)
BA   156.44 (-2.73%)
DIS   123.59 (-0.38%)
Log in
NASDAQ:APRE

Aprea Therapeutics Stock Forecast, Price & News

$25.51
-0.49 (-1.88 %)
(As of 10/27/2020 02:25 PM ET)
Add
Compare
Today's Range
$25.00
Now: $25.51▼
$25.99
50-Day Range
$21.66
MA: $26.12▼
$29.56
52-Week Range
$21.22
Now: $25.51▼
$53.11
Volume3,370 shs
Average Volume151,649 shs
Market Capitalization$540.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.2Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.42 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APRE
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.aprea.com
Phone609-510-4718
Employees14

Debt

Debt-to-Equity RatioN/A
Current Ratio7.88
Quick Ratio7.88

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.92 per share
Price / Book4.31

Profitability

EPS (Most Recent Fiscal Year)($4.67)
Net Income$-28,060,000.00
Net MarginsN/A
Return on Equity-67.57%
Return on Assets-41.86%

Miscellaneous

Outstanding Shares21,190,000
Market Cap$540.56 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$25.51
-0.49 (-1.88 %)
(As of 10/27/2020 02:25 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APRE News and Ratings via Email

Sign-up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aprea Therapeutics (NASDAQ:APRE) Frequently Asked Questions

How has Aprea Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aprea Therapeutics' stock was trading at $32.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, APRE shares have decreased by 21.6% and is now trading at $25.51.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Aprea Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Aprea Therapeutics.

When is Aprea Therapeutics' next earnings date?

Aprea Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Aprea Therapeutics.

How were Aprea Therapeutics' earnings last quarter?

Aprea Therapeutics (NASDAQ:APRE) released its earnings results on Tuesday, August, 11th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by $0.18.
View Aprea Therapeutics' earnings history.

What price target have analysts set for APRE?

5 brokers have issued 12-month target prices for Aprea Therapeutics' shares. Their forecasts range from $23.00 to $45.00. On average, they anticipate Aprea Therapeutics' share price to reach $35.80 in the next twelve months. This suggests a possible upside of 40.3% from the stock's current price.
View analysts' price targets for Aprea Therapeutics.

Are investors shorting Aprea Therapeutics?

Aprea Therapeutics saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 1,210,000 shares, a decrease of 11.0% from the August 31st total of 1,360,000 shares. Based on an average daily trading volume, of 89,800 shares, the short-interest ratio is presently 13.5 days. Approximately 9.7% of the shares of the stock are sold short.
View Aprea Therapeutics' Short Interest.

Who are some of Aprea Therapeutics' key competitors?

Some companies that are related to Aprea Therapeutics include Aimmune Therapeutics (AIMT), Xencor (XNCR), Karuna Therapeutics (KRTX), Corcept Therapeutics (CORT), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH), uniQure (QURE), Amarin (AMRN), Zymeworks (ZYME), Akcea Therapeutics (AKCA), IGM Biosciences (IGMS), Viela Bio (VIE), Cryoport (CYRX), Prestige Consumer Healthcare (PBH) and Kura Oncology (KURA).
View all competitors.

What other stocks do shareholders of Aprea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Axon Enterprise (AAXN), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN).

Who are Aprea Therapeutics' key executives?

Aprea Therapeutics' management team includes the following people:
  • Mr. Christian S. Schade, Pres, CEO & Director (Age 58)
  • Mr. Scott M. Coiante, Sr. VP & CFO (Age 52)
  • Dr. Lars Abrahmsen, Sr. VP & Chief Scientific Officer (Age 61)
  • Dr. Gregory A. Korbel, VP of Bus. Devel. (Age 43)
  • Dr. Eyal C. Attar, Sr. VP & Chief Medical Officer (Age 49)

When did Aprea Therapeutics IPO?

(APRE) raised $52 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,000,000 shares at $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.

What is Aprea Therapeutics' stock symbol?

Aprea Therapeutics trades on the NASDAQ under the ticker symbol "APRE."

Who are Aprea Therapeutics' major shareholders?

Aprea Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (1.10%). Company insiders that own Aprea Therapeutics stock include Christian S Schade, Johan Christenson, Kdev Investments Ab, Scott M Coiante, Scott M Rocklage, Vantage I LP Versant and Ventures Iv LP 5Am.
View institutional ownership trends for Aprea Therapeutics.

Which major investors are buying Aprea Therapeutics stock?

APRE stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A.. Company insiders that have bought Aprea Therapeutics stock in the last two years include Christian S Schade, Johan Christenson, Scott M Coiante, and Vantage I LP Versant.
View insider buying and selling activity for Aprea Therapeutics.

How do I buy shares of Aprea Therapeutics?

Shares of APRE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aprea Therapeutics' stock price today?

One share of APRE stock can currently be purchased for approximately $25.51.

How big of a company is Aprea Therapeutics?

Aprea Therapeutics has a market capitalization of $540.56 million. The company earns $-28,060,000.00 in net income (profit) each year or ($4.67) on an earnings per share basis. Aprea Therapeutics employs 14 workers across the globe.

What is Aprea Therapeutics' official website?

The official website for Aprea Therapeutics is www.aprea.com.

How can I contact Aprea Therapeutics?

Aprea Therapeutics' mailing address is 535 BOYLSTON STREET, BOSTON MA, 02116. The company can be reached via phone at 609-510-4718 or via email at [email protected]

This page was last updated on 10/27/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.